Tan Li

Dr. Tan Li

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2025 in Pharmacological Research
Verified
Journal Article
Open access
BPBingchen Pan
Bingchen Pan
TLTan Li
Tan Li
NDNa Deng
Na Deng
XZXin Zhang
Xin Zhang
YPYangjie Peng
Yangjie Peng
LSLiping Sun
Liping Sun
Solute carrier (SLC) transporters exert a crucial effect on metalloptosis in tumors via governing the translocation of ions and amino acids across cellular and organelle membranes. Disruptions in metal ion homeostasis mediated by SLC transporters, along with the subsequent induction of metalloptosis, are pivotal factors in tumor initiation and progression. However, the precise biological roles and clinical implications of SLC transporters in cancer remain incompletely interpreted. This review systematically summarizes the structural and functional features of SLC transporters in mediating metalloptosis and underscores their significant roles in cancer biology. We further delineate the regulatory mechanisms of SLC transporters in metal ion flux and amino acid metabolism, emphasizing their dynamic interplay in modulating metalloptosis during tumorigenesis. Furthermore, we provide a detailed overview of the complex crosstalk among SLC transporters, metal ions, and metalloptosis pathways, and highlight the role of SLC transporters in cancer, paving novel avenues for innovative anticancer strategies.

26 August 2025 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
TLTan Li
Tan Li
HSHe Sun
He Sun
YGYifei Gai
Yifei Gai
LZLingxi Zhu
Lingxi Zhu
JYJun Yang
Jun Yang
CMChunyan Ma
Chunyan Ma

26 September 2023 in Annals of Medicine
Verified
Journal Article
Open access
JJJingjing Jing
Jingjing Jing
MCMiao Chang
Miao Chang
SJShuyi Jiang
Shuyi Jiang
TWTianlong Wang
Tianlong Wang
QSQiuyan Sun
Qiuyan Sun
TLTan Li
Tan Li
Although abdominal aortic aneurysm (AAA) is associated with life-threatening complications, there are still limited reliable biomarkers for diagnostic purpose. MicroRNAs (miRNAs) have been proposed as the potential diagnostic and risk stratification markers of AAA patients, and we aim to evaluate the serum level of miR-1-3p and its diagnostic value in AAA. This study included 200 AAA patients and 200 controls. Demographic data and clinical information were collected from the subjects' medical records. Individual image analyses of AAA morphology were determined based on computed tomography angiography (CTA). The levels of serum miRNA expression were detected by quantitative real-time PCR. Bioinformatics tools were used to identify the target genes of miR-1-3p and their potential biological functions were further enriched. Serum miR-1-3p levels in the AAA group were significantly lower when compared with those in the control group in overall and subgroup comparisons. It was negatively related to WBC, CRP, maximal aneurysm diameter, area, and volume in AAA patients. Circulating miR-1-3p levels could significantly discriminate between AAA patients and healthy individuals with an area under the curve (AUC) of 0.672 (95% CI = 0.619-0.724, p < 0.001), a sensitivity of 84.5% and a specificity of 45.5%. Serum miR-1-3p was associated with a reduced risk of AAA even after adjustment for possible risk factors (OR = 0.440 per unit increase, 95% CI = 0.301-0.643, p < 0.001). And low levels of serum miR-1-3p could significantly elevate the risk of AAA in both univariate and multivariate logistic regression analyses with ORs of 4.076 and 4.136, respectively (all p < 0.001). Further GO enrichment analysis revealed that miR-1-3p was mainly involved in negative regulation of apoptotic process, sprouting angiogenesis, angiogenesis, positive regulation of blood vessel endothelial cell migration, positive regulation of cell proliferation, regulation of cell shape, etc. MiR-1-3p can be used as a promising circulating biomarker in the development of AAA, and it may participate in multiple biological processes to play a crucial role in AAA pathogenesis.

10 June 2025 in International Journal of Surgery
Verified
Journal Article
Open access
JJJingjing Jing
Jingjing Jing
MXMingda Xie
Mingda Xie
YHYanshuo Han
Yanshuo Han
TLTianyi Lin
Tianyi Lin
ZYZhiyi Ye
Zhiyi Ye
TLTan Li
Tan Li
Background: High body mass index (BMI) is a recognized risk factor for cardiovascular diseases, but its impact on aortic aneurysms (AA) remains unclear. This study analyzes the global burden of AA attributed to high BMI in 204 countries between 1990 and 2021. Methods: Using Global Burden of Disease (GBD) 2021 data, we analyzed AA-related deaths, disability-adjusted life years (DALYs), and age-standardized rates (ASRs), assessing 1990–2021 trends via estimated annual percentage change (EAPC) and projecting 2022–2040 burden with Bayesian Age-Period-Cohort (BAPC) model. The BMI-AA association was investigated through multivariable logistic regression and subgroup analyses in UK Biobank (UKB) participants, supplemented by Mendelian randomization (MR) analyses using Integrative Epidemiology Unit Open GWAS Project (IEU OpenGWAS project) summary statistics. Results: In 2021, AA deaths and DALYs due to high BMI rose to 11 540 and 247 361, respectively, compared to 1990. Despite this increase, ASMR and ASDR declined, with EAPCs of −1.36 and −1.13, respectively. The burden of AA due to high BMI increased in individuals under 45 but decreased significantly in those over 65. Males exhibited higher burden than females, though reductions were greater in males. High sociodemographic index (SDI) regions had elevated burden but declining trends. After adjusting for potential confounding factors, individuals with BMI ≥30 kg/m 2 exhibited a higher risk of AA (OR: 1.28, 95% CI: 1.13–1.46, P = 0.001) compared to those with BMI ≤23 kg/m 2 , and subgroup analyses revealed significant interactions for gender and drinking. MR was adopted to estimate the causal relationships between BMI and AA, and demonstrated that genetically predicted higher BMI was associated with an increased risk of AA. By 2040, the global burden of AA attributable to high BMI is projected to gradually rise. Conclusion: Our study highlights that high BMI-related AA remains a major global health issue, with younger men, older women, and lower SDI countries bearing greater burdens. Both UKB data and MR analyses confirm a robust link between elevated BMI and AA risk. Effective BMI management strategies are essential to reduce the future global burden of AA.

15 March 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
TLTan Li
Tan Li
JJJingjing Jing
Jingjing Jing
LSLiping Sun
Liping Sun
YGYuehua Gong
Yuehua Gong
JYJun Yang
Jun Yang
YYYuan Yuan
Yuan Yuan

23 July 2021 in Journal of Ultrasound in Medicine
Verified
Journal Article
Closed access
PDF file
HNHongxia Ning
Hongxia Ning
XLXiaozheng Liu
Xiaozheng Liu
CMChunyan Ma
Chunyan Ma
JYJun Yang
Jun Yang
TLTan Li
Tan Li